{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:36:18Z","timestamp":1792506978648,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00784-3","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:38:33Z","timestamp":1786073913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antigen Pressure, Clonal Evolution, and Lineage Plasticity in B-Cell Acute Lymphoblastic Leukemia: Resistance Biology in the Immunotherapy Era"],"prefix":"10.1007","volume":"21","author":[{"given":"Julio Alvarenga","family":"Thiebaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"9617","key":"784_CR1","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(08)60457-2.","journal-title":"Lancet"},{"issue":"19","key":"784_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1903\u201330. https:\/\/doi.org\/10.1182\/blood.2023023568.","journal-title":"Blood"},{"issue":"10","key":"784_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u201341. https:\/\/doi.org\/10.1182\/blood-2011-12-399287.","journal-title":"Blood"},{"issue":"15","key":"784_CR4","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121(15):2517\u201328. https:\/\/doi.org\/10.1002\/cncr.29383.","journal-title":"Cancer"},{"issue":"9","key":"784_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783.","journal-title":"N Engl J Med"},{"issue":"5","key":"784_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"10299","key":"784_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8.","journal-title":"Lancet"},{"issue":"5","key":"784_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1709919.","journal-title":"N Engl J Med"},{"issue":"8","key":"784_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"issue":"6","key":"784_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa033513","volume":"351","author":"A Holleman","year":"2004","unstructured":"Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351(6):533\u201342. https:\/\/doi.org\/10.1056\/NEJMoa033513.","journal-title":"N Engl J Med"},{"issue":"6","key":"784_CR11","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","volume":"14","author":"D Bhojwani","year":"2013","unstructured":"Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14(6):e205\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(12)70580-6.","journal-title":"Lancet Oncol"},{"issue":"12","key":"784_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1020.","journal-title":"Cancer Discov"},{"issue":"10","key":"784_CR13","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20136. https:\/\/doi.org\/10.1038\/s41591-018-0146-z.","journal-title":"Nat Med"},{"issue":"5","key":"784_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"J Fischer","year":"2017","unstructured":"Fischer J, Paret C, El Malki K, et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40(5):187\u201395. https:\/\/doi.org\/10.1097\/CJI.0000000000000169.","journal-title":"J Immunother"},{"issue":"10","key":"784_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442.","journal-title":"Cancer Discov"},{"issue":"7750","key":"784_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1054-1.","journal-title":"Nature"},{"issue":"1","key":"784_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138. https:\/\/doi.org\/10.1038\/nm.4441.","journal-title":"Nat Med"},{"issue":"4260","key":"784_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23\u20138. https:\/\/doi.org\/10.1126\/science.959840.","journal-title":"Science"},{"issue":"7381","key":"784_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306\u201313. https:\/\/doi.org\/10.1038\/nature10762.","journal-title":"Nature"},{"issue":"5906","key":"784_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377\u201380. https:\/\/doi.org\/10.1126\/science.1164266.","journal-title":"Science"},{"issue":"7330","key":"784_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature09650","volume":"469","author":"K Anderson","year":"2011","unstructured":"Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356\u201361. https:\/\/doi.org\/10.1038\/nature09650.","journal-title":"Nature"},{"issue":"8","key":"784_CR22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s43018-023-00604-0","volume":"4","author":"THH Coorens","year":"2023","unstructured":"Coorens THH, Collord G, Treger TD, et al. Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy. Nat Cancer. 2023;4(8):1095\u2013101. https:\/\/doi.org\/10.1038\/s43018-023-00604-0.","journal-title":"Nat Cancer"},{"issue":"17","key":"784_CR23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood.2021015036","volume":"140","author":"R Tirtakusuma","year":"2022","unstructured":"Tirtakusuma R, Szoltysek K, Milne P, et al. Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia. Blood. 2022;140(17):1875\u201390. https:\/\/doi.org\/10.1182\/blood.2021015036.","journal-title":"Blood"},{"issue":"20","key":"784_CR24","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u201310. https:\/\/doi.org\/10.1182\/blood-2015-08-665547.","journal-title":"Blood"},{"issue":"4","key":"784_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.2024026655","volume":"146","author":"SK Silbert","year":"2025","unstructured":"Silbert SK, Rankin AW, Hoang CN, et al. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025;146(4):437\u201355. https:\/\/doi.org\/10.1182\/blood.2024026655.","journal-title":"Blood"},{"issue":"10","key":"784_CR26","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499\u2013503. https:\/\/doi.org\/10.1038\/s41591-018-0201-9.","journal-title":"Nat Med"},{"issue":"2","key":"784_CR27","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1002\/ajh.26787","volume":"98","author":"V Agrawal","year":"2023","unstructured":"Agrawal V, Salhotra A, Song J, et al. The feasibility of additional CD19-targeted cellular therapy in relapsed\/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse. Am J Hematol. 2023;98(2):E38\u201340. https:\/\/doi.org\/10.1002\/ajh.26787.","journal-title":"Am J Hematol"},{"issue":"9","key":"784_CR28","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","volume":"9","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Li S, Zhang J, et al. TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025;9(9):2159\u201372. https:\/\/doi.org\/10.1182\/bloodadvances.2024014986.","journal-title":"Blood Adv"},{"issue":"4","key":"784_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","volume":"7","author":"AJ Lamble","year":"2023","unstructured":"Lamble AJ, Myers RM, Taraseviciute A, et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023;7(4):575\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2022007423.","journal-title":"Blood Adv"},{"issue":"12","key":"784_CR30","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"ME Dourthe","year":"2021","unstructured":"Dourthe ME, Rabian F, Yakouben K, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35(12):3383\u201393. https:\/\/doi.org\/10.1038\/s41375-021-01281-7.","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"784_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.HS9.0000843344.19780.98","volume":"6","author":"S Rives","year":"2022","unstructured":"Rives S, Maude SL, Hiramatsu H, et al. Tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study [abstract S112]. HemaSphere. 2022;6(Suppl 3):13\u20134. https:\/\/doi.org\/10.1097\/01.HS9.0000843344.19780.98.","journal-title":"HemaSphere"},{"key":"784_CR32","doi-asserted-by":"publisher","first-page":"1280580","DOI":"10.3389\/fimmu.2023.1280580","volume":"14","author":"A Molinos-Quintana","year":"2024","unstructured":"Molinos-Quintana A, et al. Impact of disease burden and late loss of B-cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T-cell (tisagenlecleucel) infusion in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front Immunol. 2024;14:1280580. https:\/\/doi.org\/10.3389\/fimmu.2023.1280580.","journal-title":"Front Immunol"},{"issue":"23","key":"784_CR33","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2406526.","journal-title":"N Engl J Med"},{"key":"784_CR34","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby E, Nguyen SM, Fountaine TJ, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320. https:\/\/doi.org\/10.1038\/ncomms12320.","journal-title":"Nat Commun"},{"issue":"9","key":"784_CR35","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, Song JY, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858\u201365. https:\/\/doi.org\/10.1002\/ajh.24783.","journal-title":"Am J Hematol"},{"issue":"9","key":"784_CR36","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1038\/bcj.2017.89","volume":"7","author":"CL Haddox","year":"2017","unstructured":"Haddox CL, Mangaonkar AA, Chen D, et al. Blinatumomab-induced lineage switch of B-ALL with t(4;11)(q21;q23) KMT2A\/AFF1 into an aggressive AML. Blood Cancer J. 2017;7(9):e607. https:\/\/doi.org\/10.1038\/bcj.2017.89.","journal-title":"Blood Cancer J"},{"issue":"1","key":"784_CR37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3324\/haematol.2023.283705","volume":"109","author":"A Bataller","year":"2024","unstructured":"Bataller A, Abuasab T, McCall D, et al. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica. 2024;109(1):293\u20137. https:\/\/doi.org\/10.3324\/haematol.2023.283705.","journal-title":"Haematologica"},{"issue":"3","key":"784_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1182\/blood.V64.3.701.701","volume":"64","author":"S Stass","year":"1984","unstructured":"Stass S, Mirro J Jr, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukemia. Blood. 1984;64(3):701\u20136. PMID: 6590097.","journal-title":"Blood"},{"issue":"2","key":"784_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1182\/blood.V82.2.576.576","volume":"82","author":"SC Raimondi","year":"1993","unstructured":"Raimondi SC, Pui CH, Head DR, Rivera GK, Behm FG. Cytogenetically different leukemic clones at relapse of childhood acute lymphoblastic leukemia. Blood. 1993;82(2):576\u201380. PMID: 8329712.","journal-title":"Blood"},{"key":"784_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fped.2017.00004","volume":"5","author":"AC Winters","year":"2017","unstructured":"Winters AC, Bernt KM. MLL-rearranged leukemias\u2014an update on science and clinical approaches. Front Pediatr. 2017;5:4. https:\/\/doi.org\/10.3389\/fped.2017.00004.","journal-title":"Front Pediatr"},{"issue":"1","key":"784_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","volume":"20","author":"KM Bernt","year":"2011","unstructured":"Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66\u201378. https:\/\/doi.org\/10.1016\/j.ccr.2011.06.010.","journal-title":"Cancer Cell"},{"issue":"11","key":"784_CR42","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823\u201333. https:\/\/doi.org\/10.1038\/nrc2253.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"784_CR43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ng.3230","volume":"47","author":"AK Andersson","year":"2015","unstructured":"Andersson AK, Ma J, Wang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330\u20137. https:\/\/doi.org\/10.1038\/ng.3230.","journal-title":"Nat Genet"},{"issue":"1","key":"784_CR44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3324\/haematol.2016.151035","volume":"102","author":"S Hirabayashi","year":"2017","unstructured":"Hirabayashi S, Ohki K, Nakabayashi K, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2017;102(1):118\u201329. https:\/\/doi.org\/10.3324\/haematol.2016.151035.","journal-title":"Haematologica"},{"issue":"11","key":"784_CR45","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","volume":"35","author":"S Hirabayashi","year":"2021","unstructured":"Hirabayashi S, Butler ER, Ohki K, et al. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2021;35(11):3272\u20137. https:\/\/doi.org\/10.1038\/s41375-021-01199-0.","journal-title":"Leukemia"},{"issue":"3","key":"784_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1158\/2643-3230.BCD-21-0163","volume":"3","author":"KM Dickerson","year":"2022","unstructured":"Dickerson KM, Chuang YH, Buckley S, et al. ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia. Blood Cancer Discov. 2022;3(3):240\u201363. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0163.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"784_CR47","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41375-024-02449-7","volume":"39","author":"S Qiu","year":"2025","unstructured":"Qiu S, Mei Y, Gu R, et al. The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients. Leukemia. 2025;39(1):238\u201342. https:\/\/doi.org\/10.1038\/s41375-024-02449-7.","journal-title":"Leukemia"},{"issue":"11","key":"784_CR48","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"7","key":"784_CR49","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"6","key":"784_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1309\/AJCPPVUPOTUVOIB5","volume":"142","author":"OK Weinberg","year":"2014","unstructured":"Weinberg OK, Seetharam M, Ren L, Alizadeh A, Arber DA. Mixed phenotype acute leukemia: a study of 61 cases using World Health Organization and European Group criteria. Am J Clin Pathol. 2014;142(6):803\u20138. https:\/\/doi.org\/10.1309\/AJCPPVUPOTUVOIB5.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"784_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ni1454","volume":"8","author":"C Cobaleda","year":"2007","unstructured":"Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007;8(5):463\u201370. https:\/\/doi.org\/10.1038\/ni1454.","journal-title":"Nat Immunol"},{"issue":"6","key":"784_CR52","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.immuni.2007.05.010","volume":"26","author":"SL Nutt","year":"2007","unstructured":"Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity. 2007;26(6):715\u201325. https:\/\/doi.org\/10.1016\/j.immuni.2007.05.010.","journal-title":"Immunity"},{"issue":"4","key":"784_CR53","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3324\/haematol.2017.185603","volume":"103","author":"R Marke","year":"2018","unstructured":"Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018;103(4):565\u201374. https:\/\/doi.org\/10.3324\/haematol.2017.185603.","journal-title":"Haematologica"},{"issue":"6","key":"784_CR54","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban-Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10(6):e433\u201344. https:\/\/doi.org\/10.1016\/S2352-3026(23)00073-X.","journal-title":"Lancet Haematol"},{"issue":"7","key":"784_CR55","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"issue":"18","key":"784_CR56","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood.2022019493","volume":"141","author":"OK Weinberg","year":"2023","unstructured":"Weinberg OK, Arber DA. The International Consensus Classification of acute leukemias of ambiguous lineage. Blood. 2023;141(18):2275\u20137. https:\/\/doi.org\/10.1182\/blood.2022019493.","journal-title":"Blood"},{"issue":"3","key":"784_CR57","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1002\/cpz1.383","volume":"2","author":"MJ Borowitz","year":"2022","unstructured":"Borowitz MJ, Wood BL, Keeney M, Hedley BD. Measurable residual disease detection in B-acute lymphoblastic leukemia: the Children\u2019s Oncology Group (COG) method. Curr Protoc. 2022;2(3):e383. https:\/\/doi.org\/10.1002\/cpz1.383.","journal-title":"Curr Protoc"},{"issue":"2","key":"784_CR58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ajh.25338","volume":"94","author":"NJ Short","year":"2019","unstructured":"Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. Am J Hematol. 2019;94(2):257\u201365. https:\/\/doi.org\/10.1002\/ajh.25338.","journal-title":"Am J Hematol"},{"issue":"12","key":"784_CR59","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","volume":"131","author":"B Wood","year":"2018","unstructured":"Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131(12):1350\u20139. https:\/\/doi.org\/10.1182\/blood-2017-09-806521.","journal-title":"Blood"},{"issue":"12","key":"784_CR60","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107(12):2783\u201393. https:\/\/doi.org\/10.3324\/haematol.2022.280638.","journal-title":"Haematologica"},{"issue":"12","key":"784_CR61","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","volume":"33","author":"J Pan","year":"2019","unstructured":"Pan J, Niu Q, Deng B, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019;33(12):2854\u201366. https:\/\/doi.org\/10.1038\/s41375-019-0488-7.","journal-title":"Leukemia"},{"issue":"511","key":"784_CR62","doi-asserted-by":"publisher","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","volume":"11","author":"H Qin","year":"2019","unstructured":"Qin H, Dong Z, Wang X, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019;11(511):eaaw9414. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9414.","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"784_CR63","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1182\/blood-2025-813","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, et al. BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed\/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease. Blood. 2025;146(Suppl 1):813. https:\/\/doi.org\/10.1182\/blood-2025-813.","journal-title":"Blood"},{"issue":"25","key":"784_CR64","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1182\/blood-2008-08-174228","volume":"113","author":"DA Thomas","year":"2009","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25):6330\u20137. https:\/\/doi.org\/10.1182\/blood-2008-08-174228.","journal-title":"Blood"},{"issue":"1","key":"784_CR65","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30. https:\/\/doi.org\/10.1186\/s13045-020-00856-8.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"784_CR66","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419\u201331. https:\/\/doi.org\/10.1038\/s41591-021-01436-0.","journal-title":"Nat Med"},{"issue":"5","key":"784_CR67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood.2022015795","volume":"140","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Qin H, Su A, et al. CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140(5):451\u201363. https:\/\/doi.org\/10.1182\/blood.2022015795.","journal-title":"Blood"},{"issue":"4","key":"784_CR68","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41375-021-01477-x","volume":"36","author":"X Wang","year":"2022","unstructured":"Wang X, Dong Z, Awuah D, et al. CD19\/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia. 2022;36(4):1015\u201324. https:\/\/doi.org\/10.1038\/s41375-021-01477-x.","journal-title":"Leukemia"},{"issue":"4","key":"784_CR69","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, et al. Mini-hyper-CVD plus venetoclax in patients with relapsed or refractory acute lymphoblastic leukemia. Blood Adv. 2024;8(4):909\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2023012231.","journal-title":"Blood Adv"},{"issue":"7954","key":"784_CR70","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134. https:\/\/doi.org\/10.1038\/s41586-023-05812-3.","journal-title":"Nature"},{"issue":"1","key":"784_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43(1):75\u201384. https:\/\/doi.org\/10.1200\/JCO.24.00826.","journal-title":"J Clin Oncol"},{"key":"784_CR72","unstructured":"A phase IB trial. of subcutaneous blinatumomab in combination with revumenib for patients with KMT2A-rearranged acute lymphoblastic leukemia. ClinicalTrials.gov identifier: NCT07283640."},{"key":"784_CR73","unstructured":"A phase II randomized study. of blinatumomab with or without revumenib for patients with KMT2A-translocation B-cell acute lymphoblastic leukemia\/acute leukemia of ambiguous lineage with persistent measurable residual disease. ClinicalTrials.gov identifier: NCT07636564."},{"issue":"12","key":"784_CR74","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1182\/bloodadvances.2022009480","volume":"7","author":"BM Lee","year":"2023","unstructured":"Lee BM, Summers C, Chisholm KM, et al. Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy. Blood Adv. 2023;7(12):2825\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2022009480.","journal-title":"Blood Adv"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00784-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00784-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00784-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:38:35Z","timestamp":1786073915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00784-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00784-3","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"17"}}